Directional Endothelial Communication by Polarized Extracellular Vesicle Release.

"please see the major resources table in the supplemental material mirna-sequencing data have been deposited at gene expression omnibus (geo) with the data set identifiers gse230246 (activated versus quiescent evs) and gse230289 (polarity evs).; the mass spectrometry proteomics data have been deposited to proteomexchange consortium via the proteomics identifications database (pride) partner repository with the data set identifiers pxd038914 (activated versus quiescent evs) and pxd038917 (polarity evs).; monocyte and smc rna-seq has been deposited at geo with the data set identifier gse231715.; increased sev release by activated ecs was not accompanied by increased ev biogenesis markers (eg tsg101 caveolin and flot1) at the mrna or protein level consistent with publicly available data (geo accession number: gse89970; figure s2 )."

"Disclosures N.J. Galant is a cofounder and CEO of Paradox Immunotherapeutics. The other authors report no conflicts."

"Sources of Funding This work was supported by the Canadian Institutes of Health Research (CIHR) project grants PJT178006 (K.L. Howe) and PJT148487 (J.E. Fish), National Institutes of Health grants (R01 HL136431, R01 HL141917, and R01 HL147095; E. Aikawa), Tier II Canada Research Chair from CIHR (J.E. Fish), Heart and Stroke Foundation of Canada (New Investigator Award, K.L. Howe), Vascular Cures (Wylie Scholar Award, K.L. Howe), Blair Early Career Professorship in Vascular Surgery (K.L. Howe), Peter Munk Cardiac Centre (K.L. Howe), University Health Network (K.L. Howe), and Vanier Canada Graduate Scholarship (S. Raju). Infrastructure funding was obtained from the John R. Evans Leaders Fund (J.E. Fish). W.L. Lee was supported by a Discovery Grant from the Natural Sciences and Engineering Research Council of Canada (Discovery Grants program - Individual [RGPIN] 2020-04299) and Canada Research Chair in Mechanisms of Endothelial Permeability."